

## **Cara Therapeutics Inc**

### **CORTELLIS COMPANY DETAILED PIPELINE REPORT**

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 15-Dec-2014

#### **THOMSON REUTERS**

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)



## ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

### DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 7

Product Portfolio Drug Pipeline Detail..... 10

    Phase 3 Clinical..... 11

    Phase 1 Clinical..... 17

    Discovery..... 23

[Return to Table of Contents](#)

# Cara Therapeutics Inc

## COMPANY OVERVIEW

Company Name	Cara Therapeutics Inc
Parent Company Name	Cara Therapeutics Inc
Website	http://www.caratherapeutics.com/
Country	US
Number of Drugs in Active Development	3
Number of Inactive Drugs	6
Number of Patents as Owner	15
Number of Patents as Third Party	1
Number of Deals	7
Key Indications	Pain, Pruritus, Neuropathic pain, Inflammatory disease, Adhesive capsulitis, Age related macular degeneration, Allergy, Autism, Brain injury, Bursitis, Central nervous system disease, Congestive heart failure, Depression, Diabetes mellitus, Gastrointestinal injury, Glaucoma, Hypokalemia, Ileus, Inflammatory bowel disease, Intestine disease, Intestine infection, Intestine tumor, Ischemia, Lateral epicondylitis, Liver cirrhosis, Neurodegenerative disease, Nutritional disorder, Obesity, Ocular inflammation, Osteomyelitis, Osteoporosis, Otitis, Rheumatoid
Key Target-based Actions	Opioid receptor kappa agonist, Unspecified GPCR modulator, Cannabinoid CB2 receptor agonist, Cannabinoid CB1 receptor agonist, Cannabinoid CB2 receptor modulator, G-protein coupled receptor-44 antagonist, Glucagon-like peptide 2 agonist
Key Technologies	Small molecule therapeutic, Peptide, Biological therapeutic, Oral formulation, Capsule formulation, Enteric coated formulation, Infusion, Intravenous formulation, Oral sustained release formulation, Subcutaneous formulation, Sustained release formulation, Tablet

## COMPANY PROFILE

### SUMMARY

Cara Therapeutics is a privately held company focused on developing therapeutics for pain and inflammation.

### LICENSING AGREEMENTS

In March 2006, Tripos (through its Tripos Discovery research arm) agreed to use its computational and medicinal chemistry expertise to support Cara's pain and inflammation drug programs.

### FINANCIAL

In November 2013, Cara planned to offer its common stock in an IPO. In January 2014, Cara priced the offering of 5 million common stock shares at a price of \$11 each. The underwriters were granted a 30-day option to buy up to an additional 0.75 million common stock shares at the same price to cover over-allotments. The shares began trading on the NASDAQ Global Market under the ticker symbol 'CARA'. At that time, the offering was expected to close on February 05, 2014; in February 2014, the company raised \$55.9 million from the closure of the offering.

In July 2010, Cara raised \$15 million from a series D financing round.

In November 2006, Cara raised \$19 million from the first tranche of a \$24 million series C financing round; the company closed the second tranche of \$5 million in February 2007. In July 2008, Cara raised \$12.3 million in third tranche of the series C financing round.

### EARLY R&D/TECHNOLOGY NEWS

Cara's proprietary DimerScreen technology is designed to specifically and selectively identify molecules interacting with GPCR dimers and allows for the discovery of compounds with new pharmacological properties at identified dimeric drug

[Return to Table of Contents](#)


targets.

PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

Indication	Active	Inactive	Total
Neurological disease	3	5	8
Inflammatory disease	0	1	1
Dermatological disease	1	0	1

[Return to Table of Contents](#)

## Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	1
Phase 1 Clinical	1
Discovery	1
No Development Reported	6

## DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Early Research/Development	0	0	1	0	1
Drug - Development/Commercialization License	3	0	0	0	3
Drug - Manufacturing/Supply	0	0	1	0	1
Drug - Development Services	0	0	2	0	2

[Return to Table of Contents](#)

## CLINICAL TRIALS

### Trials by Condition Studied

Condition Studied	Ongoing	All
Neurological disease	0	5
Dermatological disease	1	2
Toxicity and intoxication	0	1
Genitourinary disease	1	1
Psychiatric disorder	0	1

### Trials by Phase

Phase	Ongoing	All
Phase 2	1	5
Phase 1	0	4
Phase not specified	0	1

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

## PATENTS \*

Indication	As Owner	As Third Party	Total
Cardiovascular disease	4	1	5
Endocrine disease	3	1	4
Gastrointestinal disease	7	1	8
Genitourinary disease	3	0	3
Degeneration	2	1	3
Andrology	1	0	1
Immune disorder	6	0	6
Psychiatric disorder	1	1	2
Musculoskeletal disease	6	1	7

[Return to Table of Contents](#)





Neoplasm	2	1	3
Ocular disease	3	0	3
Genetic disorder	0	1	1
Metabolic disorder	5	1	6
Neurological disease	14	1	15
Nutritional disorder	1	1	2
Respiratory disease	1	0	1
Infectious disease	1	1	2
Injury	1	1	2
Inflammatory disease	11	0	11
Otorhinolaryngological disease	1	0	1
Gynecology and obstetrics	1	0	1
Dermatological disease	8	0	8

\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

## PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### CR-845 (iv infusion, pain/ pruritus), Cara/Ferring/Maruishi/Chong Kun Dang

#### CR-845 (iv infusion, pain/ pruritus), Cara/Ferring/Maruishi/Chong Kun Dang SNAPSHOT

Drug Name	CR-845 (iv infusion, pain/ pruritus), Cara/Ferring/Maruishi/Chong Kun Dang
Key Synonyms	
Originator Company	Cara Therapeutics Inc
Active Companies	Cara Therapeutics Inc;Maruishi Pharmaceutical Co Ltd;Ferring Pharmaceuticals SA;Chong Kun Dang Pharmaceutical Corp
Inactive Companies	
Highest Status	Phase 3 Clinical
Active Indications	Pain;Pruritus
Target-based Actions	Opioid receptor kappa agonist
Other Actions	Topical antipruritic product;Anti-inflammatory;Analgesic
Technologies	Sustained release formulation;Intravenous formulation;Infusion;Biological therapeutic;Peptide
Last Change Date	11-Nov-2014

#### CR-845 (iv infusion, pain/ pruritus), Cara/Ferring/Maruishi/Chong Kun Dang DEVELOPMENT PROFILE

##### SUMMARY

Cara Therapeutics and Ferring are developing an iv infusion formulation of CR-845 (FE-202845; MR-13A9), a long-acting, peptide-based, peripheral kappa opioid receptor agonist, for the potential treatment of pain and uremic pruritis,. In March 2009, a phase II trial for post-operative pain in women following hysterectomy began. By June 2009, phase II trials were ongoing for uremic pruritis. In June 2013, a phase II trial began in patients with post-operative pain following bunionectomy in the US. In August 2014, the first patient was dosed in a proof-of-concept phase II trial in hemodialysis patients with uremic pruritis; at that time, top-line data were expected in the first half of 2015. In October 2013, Cara planned to initiate pivotal phase III registration trials in the second half of 2014. In July 2014, human abuse liability (HAL) trial was initiated. In October 2014, positive data were reported. At that time, the company planned to advance phase III trials in the early 2015.

Licensee Chong Kun Dang Pharmaceutical (CKD) is developing the drug for post-operative pain and pruritis. In June 2013, the drug was listed as being in phase III development for pain . Licensee Maruishi Pharmaceutical is developing CR-845 (as MR-13A9) for postoperative acute pain and uremic pruritis. By December 2013, phase I development for post-operative analgesia had begun.

Cara Therapeutics was developing the agent for acute neuropathy. By June 2009, phase II trials were ongoing in neuropathy. However, no development has been reported for some time.

[Return to Table of Contents](#)

## CR-845 (iv infusion, pain/ pruritus), Cara/Ferring/Maruishi/Chong Kun Dang DEVELOPMENT STATUS

### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Chong Kun Dang Pharmaceutical Corp	Pain	South Korea	Phase 3 Clinical	28-Jun-2013
Cara Therapeutics Inc	Pain	US	Phase 2 Clinical	31-Mar-2009
Cara Therapeutics Inc	Pruritus	US	Phase 2 Clinical	09-Jun-2009
Ferring Pharmaceuticals SA	Pain	US	Phase 2 Clinical	31-Mar-2009
Maruishi Pharmaceutical Co Ltd	Pain	Japan	Phase 1 Clinical	19-Dec-2013
Chong Kun Dang Pharmaceutical Corp	Pruritus	South Korea	Discovery	29-Apr-2013
Maruishi Pharmaceutical Co Ltd	Pruritus	Japan	Discovery	26-Apr-2013
Cara Therapeutics Inc	Neuropathy	US	No Development Reported	10-Jun-2012

## CR-845 (iv infusion, pain/ pruritus), Cara/Ferring/Maruishi/Chong Kun Dang DRUG NAMES

Names	Type
FE-202845 (iv, pain), Cara/Ferring	
CR-845 (iv infusion, pain/ pruritus), Cara/Ferring/Maruishi/Chong Kun Dang	
MR-13A9/a	Research Code
MR-13A9	Research Code
CR-845	Research Code
kappa opioid agonist (intravenous, pain), Cara/Ferring	

## CR-845 (iv infusion, pain/ pruritus), Cara/Ferring/Maruishi/Chong Kun Dang CLINICAL TRIALS

### Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Pain											
0	0	0	0	0	2	0	1	0	0	0	3
Pruritus											
0	0	0	0	1	2	0	0	0	0	1	2

[Return to Table of Contents](#)

End stage renal disease											
0	0	0	0	1	1	0	0	0	0	1	1
Drug dependence											
0	0	0	0	0	0	0	0	0	1	0	1

### Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	1	4	0	1	0	1	1	6

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)


#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Cara Therapeutics Inc	2	0	1	0	3
Ferring Pharmaceuticals SA	1	0	0	0	1
Chong Kun Dang Pharmaceutical Corp	0	0	1	0	1
Maruishi Pharmaceutical Co Ltd	0	0	1	0	1

[Return to Table of Contents](#)

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	2	0	2
Drug - Early Research/Development	1	0	1

[Return to Table of Contents](#)

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Cara Therapeutics Inc	2	0	2
Maruishi Pharmaceutical Co Ltd	1	0	1

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
New use	1
Product	1



## CR-845 (oral, pain), Cara/Ferring/Chong Kun Dang

### CR-845 (oral, pain), Cara/Ferring/Chong Kun Dang SNAPSHOT

<b>Drug Name</b>	CR-845 (oral, pain), Cara/Ferring/Chong Kun Dang
<b>Key Synonyms</b>	
<b>Originator Company</b>	Cara Therapeutics Inc
<b>Active Companies</b>	Chong Kun Dang Pharmaceutical Corp;Ferring Pharmaceuticals SA;Cara Therapeutics Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 1 Clinical
<b>Active Indications</b>	Pain
<b>Target-based Actions</b>	Opioid receptor kappa agonist
<b>Other Actions</b>	Analgesic
<b>Technologies</b>	Oral formulation;Capsule formulation;Enteric coated formulation;Tablet formulation;Oral sustained release formulation;Biological therapeutic;Peptide
<b>Last Change Date</b>	03-Dec-2014

### CR-845 (oral, pain), Cara/Ferring/Chong Kun Dang DEVELOPMENT PROFILE

#### SUMMARY

Cara Therapeutics and Ferring are developing an oral enteric-coated capsule/tablet formulation of CR-845 (FE-202845), a long-acting, peptide-based, peripheral kappa opioid receptor agonist, for the potential treatment of pain, including neuropathic and inflammatory pain conditions,. Cara's Republic of Korean licensee Chong Kun Dang Pharmaceutical is also investigating the drug. By June 2009, phase I studies had begun . In November 2011, a phase I trial was initiated in the US ; in April 2012, the trial was completed and positive data were reported. In June 2014, a phase Ia/Ib trial with a tablet formulation of the drug was initiated in the US . In December 2014, the trial was completed and results were reported.

Cara Therapeutics is also developing CR-665, another kappa opioid receptor agonist and iv and subcutaneous applications of CR-845.

### CR-845 (oral, pain), Cara/Ferring/Chong Kun Dang DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Cara Therapeutics Inc	Pain	US	Phase 1 Clinical	09-Jun-2009
Ferring Pharmaceuticals SA	Pain	US	Phase 1 Clinical	09-Jun-2009
Chong Kun Dang Pharmaceutical Corp	Pain	South Korea	Discovery	29-Apr-2013

[Return to Table of Contents](#)



## CR-845 (oral, pain), Cara/Ferring/Chong Kun Dang DRUG NAMES

Names	Type
kappa opioid agonist (oral, pain), Cara/Ferring	
FE-202845 (oral, pain), Cara/Ferring	
CR-845	Research Code
CR-845 (oral, pain), Cara/Ferring/Chong Kun Dang	

## CR-845 (oral, pain), Cara/Ferring/Chong Kun Dang CLINICAL TRIALS

### Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Pain											
0	0	0	0	0	0	0	1	0	0	0	1

### Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	0	0	2	0	0	0	2

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)


#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Cara Therapeutics Inc	2	0	3	0	5
Ferring Pharmaceuticals SA	1	0	0	0	1
Unigene Laboratories Inc	1	0	0	0	1
Enteris BioPharma Inc	1	0	0	0	1
Chong Kun Dang Pharmaceutical Corp	0	0	1	0	1
Maruishi Pharmaceutical Co Ltd	0	0	1	0	1

[Return to Table of Contents](#)

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	2	0	2
Drug - Manufacturing/Supply	1	0	1
Drug - Development Services	1	0	1
Drug - Early Research/Development	1	0	1

[Return to Table of Contents](#)

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Cara Therapeutics Inc	1	0	1
Maruishi Pharmaceutical Co Ltd	1	0	1

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
Product	1

[Return to Table of Contents](#)

## CR-701

### CR-701 SNAPSHOT

Drug Name	CR-701
Key Synonyms	
Originator Company	Cara Therapeutics Inc
Active Companies	Cara Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Neuropathic pain;Pain
Target-based Actions	Cannabinoid CB1 receptor agonist;Cannabinoid CB2 receptor agonist
Other Actions	Anti-inflammatory;Analgesic
Technologies	Oral formulation;Small molecule therapeutic
Last Change Date	28-Nov-2013

### CR-701 DEVELOPMENT PROFILE

#### SUMMARY

Cara Therapeutics is investigating CR-701, an oral cannabinoid CB1/CB2 agonist, for the potential treatment of pain, including neuropathic pain,. By August 2009, preclinical studies were ongoing and positive results had been reported ; in February 2012, the drug was still listed as being in preclinical development on the company's pipeline and at that time, the company's strategy involved seeking to outlicense the drug .

Cara Therapeutics was previously investigating oral cannabinoid CB1/CB2 agonists, including CR-08 and CR-07 for the potential treatment of pain. However, no development has been reported since June 2009.

### CR-701 DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Cara Therapeutics Inc	Neuropathic pain	US	Discovery	28-Aug-2009
Cara Therapeutics Inc	Pain	US	Discovery	16-Nov-2008

[Return to Table of Contents](#)



## CR-701 DRUG NAMES

Names	Type
CR-701	Research Code
CR-07	Research Code
dual cannabinoid CB1/CB2 agonists (pain), Cara	
CR-08	Research Code

[Return to Table of Contents](#)





This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

